Canaccord Genuity Maintains a 'Buy' on Obagi Medical Products (OMPI); Resurgence From Texas To Take Longer
Tweet Send to a FriendGet Alerts OMPI Hot Sheet
Price: $23.98 --0%
Rating Summary:
0 Buy, 5 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 19 | Down: 33 | New: 12
Rating Summary:
0 Buy, 5 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 19 | Down: 33 | New: 12
Trade OMPI Now!
Canaccord Genuity maintains a 'Buy' on Obagi Medical Products (NASDAQ: OMPI) price target of $19.00 (from $21.00).
Analyst, William J. Plovanic, said, "We maintain our rating on Obagi following Q2/12 results with in-line revenues and better than expected GAAP EPS. We remain cautious, however, given the lack of clarity into the California inquiry of HQ. Additionally, the company continues to move forward with investments into its e-commerce initiative, which will depress near-term earnings. Given this uncertainty in California, the recent re-entry into the Texas market, and spending initiatives, we
believe 2012 will be a transitional year and expect investors to remain cautious.
For an analyst ratings summary and ratings history on Obagi Medical Products click here. For more ratings news on Obagi Medical Products click here.
Shares of Obagi Medical Products closed at $15.00 yesterday, with a 52 week range of $8.79-$18.00.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Analyst, William J. Plovanic, said, "We maintain our rating on Obagi following Q2/12 results with in-line revenues and better than expected GAAP EPS. We remain cautious, however, given the lack of clarity into the California inquiry of HQ. Additionally, the company continues to move forward with investments into its e-commerce initiative, which will depress near-term earnings. Given this uncertainty in California, the recent re-entry into the Texas market, and spending initiatives, we
believe 2012 will be a transitional year and expect investors to remain cautious.
For an analyst ratings summary and ratings history on Obagi Medical Products click here. For more ratings news on Obagi Medical Products click here.
Shares of Obagi Medical Products closed at $15.00 yesterday, with a 52 week range of $8.79-$18.00.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Morgan Stanley Says Tesla (TSLA) 'Top Pick in U.S. Autos'
- Biogen (BIIB) Weeks-6 TECFIDERA Scripts Continue to Ramp
- Pier 1 Imports (PIR) Sets Sights on Growing Ecommerce
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS View, Analyst PT ChangeRelated Entities
Earnings, Canaccord Genuity
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
